APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Multiple Sclerosis Drugs Industry Growth and Trends Forecast to 2032

20 December 202599 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multiple Sclerosis Drugs include ACORDA, Biogen, Mallinckrodt, Bayer, Merck KGaA, Novartis, Sanofi and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Multiple Sclerosis Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Multiple Sclerosis Drugs market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Multiple Sclerosis Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Multiple Sclerosis Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Multiple Sclerosis Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Multiple Sclerosis Drugs Market by Company

ACORDA

Biogen

Mallinckrodt

Bayer

Merck KGaA

Novartis

Sanofi

Teva

Multiple Sclerosis Drugs Segment by Type

Injectable Medications

Oral Medications

Others

Multiple Sclerosis Drugs Segment by Application

Adults

Children

Multiple Sclerosis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multiple Sclerosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Multiple Sclerosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injectable Medications Table 2. Major Company of Oral Medications Table 3. Major Company of Others Table 4. Global Multiple Sclerosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 6. Global Multiple Sclerosis Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Multiple Sclerosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Multiple Sclerosis Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Multiple Sclerosis Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global Multiple Sclerosis Drugs Sales by Type (2027-2032) & (W Units) Table 11. Global Multiple Sclerosis Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Multiple Sclerosis Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Multiple Sclerosis Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Multiple Sclerosis Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 16. North America Multiple Sclerosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 18. Europe Multiple Sclerosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 20. Asia-Pacific Multiple Sclerosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 22. Latin America Multiple Sclerosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 24. Middle East and Africa Multiple Sclerosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Multiple Sclerosis Drugs Industry Trends Table 26. Multiple Sclerosis Drugs Industry Drivers Table 27. Multiple Sclerosis Drugs Industry Opportunities and Challenges Table 28. Multiple Sclerosis Drugs Industry Restraints Table 29. Global Multiple Sclerosis Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Multiple Sclerosis Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Multiple Sclerosis Drugs Sales by Company (2021-2026) & (W Units) Table 32. Global Multiple Sclerosis Drugs Sales Share by Company (2021-2026) Table 33. Global Multiple Sclerosis Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Multiple Sclerosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Multiple Sclerosis Drugs Major Company Production Sites and Headquarters Table 36. Global Multiple Sclerosis Drugs Company, Product Type & Application Table 37. Global Multiple Sclerosis Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Multiple Sclerosis Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Multiple Sclerosis Drugs Sales by Region (2021-2026) & (W Units) Table 42. Global Multiple Sclerosis Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Multiple Sclerosis Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Multiple Sclerosis Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Multiple Sclerosis Drugs Sales by Region (2027-2032) & (W Units) Table 47. Global Multiple Sclerosis Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Multiple Sclerosis Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Multiple Sclerosis Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Multiple Sclerosis Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Multiple Sclerosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 53. Global Multiple Sclerosis Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Multiple Sclerosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Multiple Sclerosis Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Multiple Sclerosis Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Multiple Sclerosis Drugs Sales by Application (2027-2032) & (W Units) Table 58. Global Multiple Sclerosis Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Multiple Sclerosis Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Multiple Sclerosis Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Multiple Sclerosis Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 63. North America Multiple Sclerosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 65. Europe Multiple Sclerosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 67. Asia-Pacific Multiple Sclerosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 69. Latin America Multiple Sclerosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 71. Middle East and Africa Multiple Sclerosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. ACORDA Company Information Table 73. ACORDA Business Overview Table 74. ACORDA Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. ACORDA Multiple Sclerosis Drugs Product Portfolio Table 76. ACORDA Recent Development Table 77. Biogen Company Information Table 78. Biogen Business Overview Table 79. Biogen Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Biogen Multiple Sclerosis Drugs Product Portfolio Table 81. Biogen Recent Development Table 82. Mallinckrodt Company Information Table 83. Mallinckrodt Business Overview Table 84. Mallinckrodt Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Mallinckrodt Multiple Sclerosis Drugs Product Portfolio Table 86. Mallinckrodt Recent Development Table 87. Bayer Company Information Table 88. Bayer Business Overview Table 89. Bayer Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Bayer Multiple Sclerosis Drugs Product Portfolio Table 91. Bayer Recent Development Table 92. Merck KGaA Company Information Table 93. Merck KGaA Business Overview Table 94. Merck KGaA Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Merck KGaA Multiple Sclerosis Drugs Product Portfolio Table 96. Merck KGaA Recent Development Table 97. Novartis Company Information Table 98. Novartis Business Overview Table 99. Novartis Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Novartis Multiple Sclerosis Drugs Product Portfolio Table 101. Novartis Recent Development Table 102. Sanofi Company Information Table 103. Sanofi Business Overview Table 104. Sanofi Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Sanofi Multiple Sclerosis Drugs Product Portfolio Table 106. Sanofi Recent Development Table 107. Teva Company Information Table 108. Teva Business Overview Table 109. Teva Multiple Sclerosis Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Teva Multiple Sclerosis Drugs Product Portfolio Table 111. Teva Recent Development Table 112. North America Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 113. North America Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 114. North America Multiple Sclerosis Drugs Sales Market Share by Country (2021-2026) Table 115. North America Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 116. North America Multiple Sclerosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 117. North America Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. North America Multiple Sclerosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 119. North America Multiple Sclerosis Drugs Market Share by Country (2021-2026) Table 120. North America Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. North America Multiple Sclerosis Drugs Market Share Forecast by Country (2027-2032) Table 122. Europe Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 123. Europe Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 124. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2021-2026) Table 125. Europe Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 126. Europe Multiple Sclerosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 127. Europe Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Europe Multiple Sclerosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 129. Europe Multiple Sclerosis Drugs Market Share by Country (2021-2026) Table 130. Europe Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Europe Multiple Sclerosis Drugs Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 134. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share by Country (2021-2026) Table 135. Asia-Pacific Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 136. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Multiple Sclerosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 139. Asia-Pacific Multiple Sclerosis Drugs Market Share by Country (2021-2026) Table 140. Asia-Pacific Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Asia-Pacific Multiple Sclerosis Drugs Market Share Forecast by Country (2027-2032) Table 142. Latin America Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 143. Latin America Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 144. Latin America Multiple Sclerosis Drugs Sales Market Share by Country (2021-2026) Table 145. Latin America Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 146. Latin America Multiple Sclerosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 147. Latin America Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Latin America Multiple Sclerosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 149. Latin America Multiple Sclerosis Drugs Market Share by Country (2021-2026) Table 150. Latin America Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Latin America Multiple Sclerosis Drugs Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 154. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2021-2026) Table 155. Middle East and Africa Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 156. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Multiple Sclerosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 159. Middle East and Africa Multiple Sclerosis Drugs Market Share by Country (2021-2026) Table 160. Middle East and Africa Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Middle East and Africa Multiple Sclerosis Drugs Market Share Forecast by Country (2027-2032) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Multiple Sclerosis Drugs Distributors List Table 165. Multiple Sclerosis Drugs Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. Multiple Sclerosis Drugs Image Figure 2. Global Multiple Sclerosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis Drugs Sales (2021-2032) & (W Units) Figure 5. Injectable Medications Image Figure 6. Global Injectable Medications Sales YoY Growth (2021-2032) & (W Units) Figure 7. Oral Medications Image Figure 8. Global Oral Medications Sales YoY Growth (2021-2032) & (W Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 11. Global Multiple Sclerosis Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Multiple Sclerosis Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Multiple Sclerosis Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Multiple Sclerosis Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Multiple Sclerosis Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Multiple Sclerosis Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Multiple Sclerosis Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Multiple Sclerosis Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Multiple Sclerosis Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Adults Image Figure 26. Global Adults Sales YoY Growth (2021-2032) & (W Units) Figure 27. Children Image Figure 28. Global Children Sales YoY Growth (2021-2032) & (W Units) Figure 29. Global Multiple Sclerosis Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Multiple Sclerosis Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Multiple Sclerosis Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Multiple Sclerosis Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Multiple Sclerosis Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Multiple Sclerosis Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Multiple Sclerosis Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Multiple Sclerosis Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 42. North America Multiple Sclerosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Multiple Sclerosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 46. Europe Multiple Sclerosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Multiple Sclerosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. Asia-Pacific Multiple Sclerosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Multiple Sclerosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Latin America Multiple Sclerosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Multiple Sclerosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Multiple Sclerosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Middle East and Africa Multiple Sclerosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Multiple Sclerosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Multiple Sclerosis Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Multiple Sclerosis Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Injectable Medications
  • Oral Medications
  • Others
Applications
  • Adults
  • Children
Companies covered
  • ACORDA
  • Biogen
  • Mallinckrodt
  • Bayer
  • Merck KGaA
  • Novartis
  • Sanofi
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multiple Sclerosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Multiple Sclerosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Multiple Sclerosis Drugs Market by Type
  6. 1.3.1 Injectable Medications
  7. 1.3.2 Oral Medications
  8. 1.3.3 Others
  9. 1.4 Global Multiple Sclerosis Drugs Market Size by Type
  10. 1.4.1 Global Multiple Sclerosis Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Multiple Sclerosis Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Multiple Sclerosis Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Multiple Sclerosis Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Multiple Sclerosis Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Multiple Sclerosis Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Multiple Sclerosis Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Multiple Sclerosis Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Multiple Sclerosis Drugs Industry Trends
  2. 2.2 Multiple Sclerosis Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Multiple Sclerosis Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Multiple Sclerosis Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Multiple Sclerosis Drugs Price (2021-2026)
  4. 3.4 Global Multiple Sclerosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multiple Sclerosis Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Multiple Sclerosis Drugs Company, Product Type & Application
  7. 3.7 Global Multiple Sclerosis Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multiple Sclerosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multiple Sclerosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multiple Sclerosis Drugs Tier 1, Tier 2, and Tier 3
4 Multiple Sclerosis Drugs Regional Status and Outlook
  1. 4.1 Global Multiple Sclerosis Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Multiple Sclerosis Drugs Historic Market Size by Region
  3. 4.2.1 Global Multiple Sclerosis Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Multiple Sclerosis Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Multiple Sclerosis Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Multiple Sclerosis Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Multiple Sclerosis Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Multiple Sclerosis Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Multiple Sclerosis Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Multiple Sclerosis Drugs by Application
  1. 5.1 Multiple Sclerosis Drugs Market by Application
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Multiple Sclerosis Drugs Market Size by Application
  5. 5.2.1 Global Multiple Sclerosis Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Multiple Sclerosis Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Multiple Sclerosis Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Multiple Sclerosis Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Multiple Sclerosis Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Multiple Sclerosis Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Multiple Sclerosis Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Multiple Sclerosis Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ACORDA
  2. 6.1.1 ACORDA Company Information
  3. 6.1.2 ACORDA Business Overview
  4. 6.1.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ACORDA Multiple Sclerosis Drugs Product Portfolio
  6. 6.1.5 ACORDA Recent Developments
  7. 6.2 Biogen
  8. 6.2.1 Biogen Company Information
  9. 6.2.2 Biogen Business Overview
  10. 6.2.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Biogen Multiple Sclerosis Drugs Product Portfolio
  12. 6.2.5 Biogen Recent Developments
  13. 6.3 Mallinckrodt
  14. 6.3.1 Mallinckrodt Company Information
  15. 6.3.2 Mallinckrodt Business Overview
  16. 6.3.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio
  18. 6.3.5 Mallinckrodt Recent Developments
  19. 6.4 Bayer
  20. 6.4.1 Bayer Company Information
  21. 6.4.2 Bayer Business Overview
  22. 6.4.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bayer Multiple Sclerosis Drugs Product Portfolio
  24. 6.4.5 Bayer Recent Developments
  25. 6.5 Merck KGaA
  26. 6.5.1 Merck KGaA Company Information
  27. 6.5.2 Merck KGaA Business Overview
  28. 6.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio
  30. 6.5.5 Merck KGaA Recent Developments
  31. 6.6 Novartis
  32. 6.6.1 Novartis Company Information
  33. 6.6.2 Novartis Business Overview
  34. 6.6.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Novartis Multiple Sclerosis Drugs Product Portfolio
  36. 6.6.5 Novartis Recent Developments
  37. 6.7 Sanofi
  38. 6.7.1 Sanofi Company Information
  39. 6.7.2 Sanofi Business Overview
  40. 6.7.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sanofi Multiple Sclerosis Drugs Product Portfolio
  42. 6.7.5 Sanofi Recent Developments
  43. 6.8 Teva
  44. 6.8.1 Teva Company Information
  45. 6.8.2 Teva Business Overview
  46. 6.8.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Teva Multiple Sclerosis Drugs Product Portfolio
  48. 6.8.5 Teva Recent Developments
7 North America by Country
  1. 7.1 North America Multiple Sclerosis Drugs Sales by Country
  2. 7.1.1 North America Multiple Sclerosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Multiple Sclerosis Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Multiple Sclerosis Drugs Market Size by Country
  6. 7.2.1 North America Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Multiple Sclerosis Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Multiple Sclerosis Drugs Sales by Country
  2. 8.1.1 Europe Multiple Sclerosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Multiple Sclerosis Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Multiple Sclerosis Drugs Market Size by Country
  6. 8.2.1 Europe Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Multiple Sclerosis Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Multiple Sclerosis Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Multiple Sclerosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Multiple Sclerosis Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Multiple Sclerosis Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Multiple Sclerosis Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Multiple Sclerosis Drugs Sales by Country
  2. 10.1.1 South America Multiple Sclerosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Multiple Sclerosis Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Multiple Sclerosis Drugs Market Size by Country
  6. 10.2.1 South America Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Multiple Sclerosis Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Multiple Sclerosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Multiple Sclerosis Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Multiple Sclerosis Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Multiple Sclerosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Multiple Sclerosis Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Multiple Sclerosis Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Multiple Sclerosis Drugs Value Chain Analysis
  2. 12.1.1 Multiple Sclerosis Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Multiple Sclerosis Drugs Production Mode & Process
  7. 12.2 Multiple Sclerosis Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Multiple Sclerosis Drugs Distributors
  10. 12.2.3 Multiple Sclerosis Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst